Antimicrobial sensitivity and treatment of Helicobacter pylori infections

• Published in: הרפואה Vol. 126; no. 3; p. 126
• Main Authors: Moshkowitz, M, Santo, M, Hallak, A, Arber, N, Tiomny, E, Peled, Y, Gorea, A, Gilat, T
• Format: Journal Article
• Language: Hebrew
• Published: Israel 01.02.1994
• Subjects: Amoxicillin - therapeutic use; Amoxicillin - toxicity; Anti-Bacterial Agents - therapeutic use; Anti-Bacterial Agents - toxicity; Female; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter pylori - drug effects; Humans; Male; Metronidazole - therapeutic use; Metronidazole - toxicity; Microbial Sensitivity Tests; Tetracycline - therapeutic use; Tetracycline - toxicity
• ISSN: 0017-7768

Helicobacter pylori (HP) is considered the etiological agent of chronic active gastritis and suspicion is strong that it plays an important role in duodenal ulcer. Recently, several clinical studies reported that eradication of HP markedly reduces the frequency of ulcer relapse. Triple-drug treatment, including a bismuth salt and 2 antibiotics (usually metronidazole with either amoxycillin or tetracycline) is considered the treatment of choice. It has been shown that the most important factor for predicting success of treatment is the sensitivity of HP to metronidazole, which varies considerably. In the present study we evaluated antimicrobial susceptibility of 18 HP clinical isolates, as well as effectiveness of triple therapy for eradicating HP infections in 65 patients. In vitro, HP was highly sensitive to amoxycillin, erythromycin and tetracycline (100%), and also to metronidazole and tinidazole (94%). Sensitivity to chloramphenicol was low (50%). In our clinical study, the overall eradication rate was 66%; it was higher among women (80%) than men (54%), probably due to better compliance. It is concluded that HP strains in Israel are highly sensitive to metronidazole and that triple therapy is effective, providing compliance is good.